Marketdash
Back to News

Virax Biolabs Stock Retreats After Hours Despite 75% Intraday Surge

MarketDash Editorial Team
4 days ago
Virax Biolabs shares dropped 12.79% in after-hours trading to $0.60 after announcing a $5 million private placement, cooling off from a dramatic 75% rally during Wednesday's regular session.

Virax Biolabs Group Ltd (VRAX) gave back some of Wednesday's impressive gains in after-hours trading, declining 12.79% to $0.60 following news of a dilutive financing deal.

The biotech stock had closed Wednesday's regular session at $0.69, up a remarkable 75.11% from the previous day. But the celebration proved short-lived once the private placement details hit the tape.

The Financing Deal

The London-based biotechnology company announced definitive agreements to sell 12.5 million ordinary shares at $0.40 per share through a private placement. That's a steep discount to where the stock closed on Wednesday, which helps explain the after-hours selloff.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction. Gross proceeds are expected to hit $5 million before deducting fees and expenses.

Warrant Adjustments

The offering includes preferred investment options priced at $0.40 per share, exercisable immediately with a five-year term. But here's where it gets interesting for existing investors: Virax will reduce the exercise prices on its 2023 Series A and Series B preferred investment options down to $0.40 to match the new offering. The company is also extending their expiration to five years from when the Initial Registration Statement becomes effective.

That's a meaningful reset for warrant holders, though the dilution from the new shares probably stings.

What's Next

The transaction is expected to close on or about Thursday, subject to customary closing conditions. Virax plans to use the net proceeds for working capital and general corporate purposes—the classic "keeping the lights on" language.

The securities haven't been registered under the Securities Act of 1933 and are being sold in a transaction that doesn't involve a public offering.

The Bigger Picture

Wednesday's 75% rally was dramatic, but zoom out and the picture looks rougher. VRAX is down 68.87% year-to-date. The company currently carries a market capitalization of just $3.01 million and trades within a 52-week range of $0.35 to $3.20.

For context, market data indicates that VRAX stock has shown a negative price trend across all timeframes, suggesting Wednesday's pop was more of an outlier than a trend reversal.

Back to News

Virax Biolabs Stock Retreats After Hours Despite 75% Intraday Surge

MarketDash Editorial Team
4 days ago
Virax Biolabs shares dropped 12.79% in after-hours trading to $0.60 after announcing a $5 million private placement, cooling off from a dramatic 75% rally during Wednesday's regular session.

Virax Biolabs Group Ltd (VRAX) gave back some of Wednesday's impressive gains in after-hours trading, declining 12.79% to $0.60 following news of a dilutive financing deal.

The biotech stock had closed Wednesday's regular session at $0.69, up a remarkable 75.11% from the previous day. But the celebration proved short-lived once the private placement details hit the tape.

The Financing Deal

The London-based biotechnology company announced definitive agreements to sell 12.5 million ordinary shares at $0.40 per share through a private placement. That's a steep discount to where the stock closed on Wednesday, which helps explain the after-hours selloff.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction. Gross proceeds are expected to hit $5 million before deducting fees and expenses.

Warrant Adjustments

The offering includes preferred investment options priced at $0.40 per share, exercisable immediately with a five-year term. But here's where it gets interesting for existing investors: Virax will reduce the exercise prices on its 2023 Series A and Series B preferred investment options down to $0.40 to match the new offering. The company is also extending their expiration to five years from when the Initial Registration Statement becomes effective.

That's a meaningful reset for warrant holders, though the dilution from the new shares probably stings.

What's Next

The transaction is expected to close on or about Thursday, subject to customary closing conditions. Virax plans to use the net proceeds for working capital and general corporate purposes—the classic "keeping the lights on" language.

The securities haven't been registered under the Securities Act of 1933 and are being sold in a transaction that doesn't involve a public offering.

The Bigger Picture

Wednesday's 75% rally was dramatic, but zoom out and the picture looks rougher. VRAX is down 68.87% year-to-date. The company currently carries a market capitalization of just $3.01 million and trades within a 52-week range of $0.35 to $3.20.

For context, market data indicates that VRAX stock has shown a negative price trend across all timeframes, suggesting Wednesday's pop was more of an outlier than a trend reversal.